No Data
Evercore Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $22
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $60
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating